Skip to main content
Adaptimmune Therapeutics PLC logo

Adaptimmune Therapeutics PLC — Investor Relations & Filings

Ticker · ADAP ISIN · US00653A1079 LEI · 549300UUNWK8TRT5EW12 US Manufacturing
Open in API
Filings indexed 807 across all filing types
Latest filing 2015-11-12 Report Publication Anno…
Country GB United Kingdom
Listing US ADAP

About Adaptimmune Therapeutics PLC

https://www.adaptimmune.com/

Adaptimmune Therapeutics is a commercial-stage biopharmaceutical company specializing in the development of novel T-cell receptor (TCR) T-cell therapies for cancer. The company utilizes a proprietary platform to engineer a patient's own T-cells to recognize and fight solid tumors. Its first FDA-approved therapy, Tecelra (afami-cel), is a treatment for advanced synovial sarcoma. Adaptimmune is advancing a robust pipeline of cell therapies, including preclinical programs targeting PRAME and CD70, as well as an allogeneic platform. The company's mission is to deliver transformative, potentially single-infusion treatments to reshape cancer care for patients with difficult-to-treat solid tumors.

Recent filings

Filing Released Lang Actions
6-K
Report Publication Announcement Classification · 95% confidence The document is a Form 6-K filed by a foreign private issuer, Adaptimmune Therapeutics plc, reporting the publication of its UK Annual Report and Accounts for the year ended June 30, 2015. The text states that the UK Annual Report is available on the company's website and that the notice of the AGM is attached as an exhibit. The document itself does not contain the full annual report or detailed financial data but rather announces the publication and availability of the report and AGM notice. The document length is 3884 characters, which is relatively short and consistent with an announcement rather than the full report. According to the 'MENU VS MEAL' rule, this is an announcement of a report, not the report itself. Therefore, the appropriate classification is Report Publication Announcement (RPA).
2015-11-12 English
6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by a foreign private issuer, Adaptimmune Therapeutics plc, with the SEC. It reports 'Other Events' including a press release and an updated corporate presentation related to clinical program data and preclinical safety assessments. The document is relatively short (2712 characters) and primarily announces the release of a press release and presentation materials, which are attached as exhibits. There is no substantive financial data or detailed report content within the text itself. According to the 'MENU VS MEAL' rule, this is an announcement of reports (press release and presentation) rather than the reports themselves. Therefore, the appropriate classification is Regulatory Filings (RNS), which serves as a fallback for miscellaneous filings that do not fit other categories.
2015-11-05 English
6-K
Director's Dealing Classification · 95% confidence The document is a Form 6-K filed by Adaptimmune Therapeutics plc, which is a report of a foreign private issuer pursuant to SEC rules. It provides details about recent open market purchases of American Depositary Shares by company officers, specifically insider transactions by the CEO and Chief Medical Officer. The document also mentions the company's transition from foreign private issuer to domestic filer status and includes general company information and forward-looking statements. There are no financial statements, earnings data, or detailed management discussion of financial results. The primary content is about insider share purchases, which corresponds to reports of personal share transactions by company directors and executives. Therefore, the document fits the category of Director's Dealing (DIRS). The document length is 6959 characters, which is sufficient to contain substantive information, not just an announcement or certification. Hence, the classification is DIRS with high confidence.
2015-10-22 English
6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by a foreign private issuer, Adaptimmune Therapeutics plc, with the SEC. It reports on other events, specifically announcing a press release and presentation materials related to the company's participation in the 2015 BIO Investor Forum. The document includes no financial statements or detailed financial analysis but rather serves as an announcement of these events and attached exhibits. The length is 2344 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this document is best classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories and often include such announcements and exhibits.
2015-10-19 English
20-F
Annual Report FY 2015
2015-10-13 English
6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by a foreign private issuer, Adaptimmune Therapeutics plc, with the SEC. It announces the issuance of a press release dated October 13, 2015, which contains the company's full fiscal year 2015 financial results and details about an earnings call and webcast. The document itself does not contain the financial results but references the press release as an exhibit. The document length is short (2085 characters), and it primarily serves as an announcement of the press release and earnings call information rather than the report itself. According to the 'Menu vs Meal' rule, this is an announcement of a report, not the report itself. Therefore, the appropriate classification is Regulatory Filings (RNS), which is the fallback category for such announcements and miscellaneous filings that do not fit other categories.
2015-10-13 English

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.